製品名:5-bromo-2-methylpyrimidine

IUPAC Name:5-bromo-2-methylpyrimidine

CAS番号:7752-78-5
分子式:C5H5BrN2
純度:97%
カタログ番号:CM104177
分子量:173.01

包装単位 有効在庫 価格(USD) 数量
CM104177-100g in stock Ȁƞǯ
CM104177-250g in stock ǕƏȀ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:7752-78-5
分子式:C5H5BrN2
融点:-
SMILESコード:CC1=NC=C(Br)C=N1
密度:
カタログ番号:CM104177
分子量:173.01
沸点:
MDL番号:MFCD07375143
保管方法:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.